Announcements Trials
Browse Landscape

Phase

Phase 2 17Phase 1 11Phase 1/2 8Phase 3 3Phase EARLY_PHASE1 2Phase 4 2Phase 2/3 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other solid neoplasm 1Myeloid 1Gastrointestinal 1

Conditions

Recurrence 1Neoplasms 1Lymphoma, T-Cell 1Lymphoma 1

Interventions

Cyclophosphamide 21fludarabine 12Rituximab 10Vincristine 6Etoposide 6Prednisone 5Doxorubicin 5pembrolizumab 4Radiotherapy 4Methotrexate 4Magnetic Resonance Spectroscopy 4Immunotherapy, Adoptive 4Granulocyte Colony-Stimulating Factor 4Filgrastim 4Dexamethasone 4venetoclax 3ibrutinib 3Nivolumab 3Imiquimod 3Ifosfamide 3Exercise 3Biopsy 368Ga-pentixafor 3fludarabine phosphate 2daratumumab 2Transplantation 2Stem Cell Transplantation 2Specimen Handling 2Sirolimus 2Roflumilast 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Decitabine × Lymphoid × Clear all
NCT03445858 2026-02-18

Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults

Children's Hospital Medical Center, Cincinnati

Phase EARLY_PHASE1 Completed
22 enrolled
Lymphoid

Lymphoma, Neoplasms, Recurrence

NCT02846935 2019-01-07

p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies

Case Comprehensive Cancer Center

Phase EARLY_PHASE1 Completed
7 enrolled
Lymphoid

Lymphoma, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡